Temporal Arteritis Market By Drug Class (Corticosteroids, Interleukin-6 Inhibitors, Immunosuppressants, JAK Inhibitors); By Route of Administration (Oral, Parenteral); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Is the Temporal Arteritis Market Evolving, and What Is Driving Its Growth? – (Updated On: 07-Sep-2026)

The Global Temporal Arteritis, or Giant Cell Arteritis (GCA), Market was valued at USD 1.58 billion in 2025 and is projected to reach USD 2.61 billion by 2032, expanding at a 7.43% CAGR during 2026–2032, based on the supplied market estimate. GCA is an inflammatory disease of medium- and large-sized arteries that occurs almost exclusively after age 50 and can cause irreversible ocular and vascular complications.

 

The patient base is concentrated in older adults. Approximately 220,000–228,000 people in the United States are estimated to have GCA, with women affected around two to three times more often than men. A global meta-analysis estimated incidence at 10.0 cases per 100,000 people aged over 50 and prevalence at 51.74 per 100,000, with incidence highest in Scandinavia at 21.57 per 100,000.

 

The urgency of treatment creates a strong clinical demand. Permanent vision loss has historically occurred in approximately 15–20% of patients before treatment, and one cohort found permanent vision loss in 17.4% of GCA patients, with nearly 88% of those events occurring before therapy began. This makes rapid diagnosis and immediate treatment central to disease management.

 

High-dose glucocorticoids remain the initial treatment foundation, but prolonged exposure creates substantial toxicity and drives demand for steroid-sparing therapies. Tocilizumab established biologic treatment in GCA, while upadacitinib received FDA approval on April 28, 2025 for adults with GCA. Its pivotal 428-patient Phase 3 study demonstrated corticosteroid-free sustained remission using a 26-week steroid taper.

 

Market development is therefore increasingly tied to an aging at-risk population, the consequences of delayed diagnosis, recurrent disease requiring long-term management, and wider adoption of targeted steroid-sparing therapies.

 

Leading and Fastest-Growing Segments in the Temporal Arteritis Market

By Drug Class

• Leading Segment – Corticosteroids: Corticosteroids led the Temporal Arteritis Market with a 46.0% share, valued at approximately USD 0.727 billion in 2025. Their leadership reflects their central role in rapidly controlling arterial inflammation and reducing the risk of serious ischemic complications, particularly at treatment initiation. However, their 5.0% CAGR is comparatively moderate because prolonged steroid exposure encourages physicians to use steroid-sparing therapies where appropriate.

• Fastest-Growing Segment – JAK Inhibitors: JAK inhibitors are projected to record the fastest growth at a 13.2% CAGR during 2026–2032, from a 7.0% share and USD 0.111 billion in 2025. Growth is supported by the 2025 approval of Rinvoq (upadacitinib) for giant cell arteritis, which adds an oral targeted option and expands treatment choice beyond corticosteroids and injectable biologics.

 

By Route of Administration

• Leading Segment – Oral: Oral therapies accounted for the largest share at 58.0%, representing approximately USD 0.916 billion in 2025. The segment benefits from extensive use of oral corticosteroids and immunosuppressants, together with the addition of oral targeted therapy such as upadacitinib, making oral administration highly relevant across both initial and longer-term outpatient management.

• Fastest-Growing Segment – Parenteral: Parenteral therapies are projected to grow faster at a 8.8% CAGR, compared with 6.4% for oral therapies. Their expansion is linked mainly to higher-value injectable biologics, particularly IL-6 inhibitors, and continued use of intravenous treatment in patients with severe or vision-threatening disease.

 

By Distribution Channel

• Leading Segment – Hospital Pharmacies: Hospital pharmacies led with a 48.0% market share, valued at approximately USD 0.758 billion in 2025. Their position reflects the specialist-led nature of GCA management, including urgent treatment initiation, management of severe complications, biologic therapy and coordination between rheumatology and ophthalmology services.

• Fastest-Growing Segment – Online Pharmacies: Online pharmacies are projected to register the fastest CAGR of 10.6%, from a 15.0% share and USD 0.237 billion in 2025. Growth is supported by refill-based access, home delivery and increasing use of oral maintenance therapies among clinically stable patients managed outside acute-care settings.

 

By Geography

• Leading Region – North America: North America dominated the Temporal Arteritis Market with a 42.0% share, valued at approximately USD 0.664 billion in 2025. Its leadership is supported by a comparatively high diagnosed GCA burden among older adults, established rheumatology and ophthalmology infrastructure, advanced diagnostic imaging, and availability of targeted treatments including tocilizumab and upadacitinib.

• Fastest-Growing Region – Asia Pacific: Asia Pacific is projected to record the fastest regional growth at a 8.7% CAGR during 2026–2032, from an 18.0% share and USD 0.284 billion in 2025. Expansion is supported by aging populations, improving disease recognition, wider specialist access and increasing availability of targeted therapies, with Japan providing one of the region's most structured GCA diagnosis, treatment and reimbursement pathways.

 

Drug-Class Innovation Redefining the Temporal Arteritis Market

Corticosteroids remain the primary and most important treatment for temporal arteritis (giant cell arteritis), as they rapidly suppress arterial inflammation and help prevent serious complications, particularly permanent vision loss and blindness. Their established clinical role also drives strong demand within the temporal arteritis market. In 2025, corticosteroids accounted for 46.0% of the market, valued at USD 0.727 billion. The segment is projected to grow at a CAGR of 5.0% from 2026 to 2032, reflecting their continued importance in disease management.

Interleukin-6 (IL-6) inhibitors, including tocilizumab, have emerged as important steroid-sparing therapies for temporal arteritis, also known as giant cell arteritis (GCA). By targeting IL-6-driven inflammation, these treatments help patients achieve and maintain sustained remission while reducing reliance on corticosteroids and minimizing their cumulative exposure. Reflecting their growing clinical importance, IL-6 inhibitors accounted for 28.0% of the market, valued at USD 0.442 billion in 2025, and are expected to expand at a CAGR of 10.0% during the forecast period over time.

Immunosuppressants accounted for 19.0% share, representing USD 0.300 billion in 2025, and are expected to expand at a CAGR of 6.4%. Methotrexate is the principal conventional steroid-sparing option and remains relevant where tocilizumab is unsuitable, inaccessible or not preferred. German claims evidence illustrates continued real-world utilization: among incident GCA patients followed for two years, methotrexate use reached 26.7% in the 2020 cohort compared with 14.1% for tocilizumab. ACR guidance also recognizes methotrexate as an alternative glucocorticoid-sparing therapy, although evidence supporting tocilizumab is stronger.

JAK inhibitors held 7.0% share, representing USD 0.111 billion in 2025, but are projected to register the fastest drug-class CAGR of 13.2%. AbbVie's Rinvoq is the principal commercial catalyst following its April 2025 FDA approval for adults with GCA. Unlike IL-6 biologics, upadacitinib is an oral targeted therapy, creating differentiation around route of administration as well as mechanism. SELECT-GCA enrolled 429 patients, and its sustained-remission results established the evidence base supporting regulatory expansion into GCA.

 

Route of Administration Reshaping the Temporal Arteritis Market Treatment Mix

Oral therapies accounted for 58.0% of the market, representing USD 0.916 billion in 2025, and are projected to expand at a CAGR of 6.4% during 2026–2032. Oral corticosteroids dominate initial and tapering treatment, while methotrexate contributes to longer-term steroid-sparing management. Rinvoq adds a higher-value oral targeted treatment to a route previously dominated commercially by low-cost conventional medicines. Its once-daily oral format differentiates it from injectable IL-6 therapies and may be relevant for suitable patients managed primarily in outpatient rheumatology settings.

Parenteral therapies represented 42.0% of the Temporal Arteritis Market, valued at USD 0.664 billion in 2025, and are projected to grow at a CAGR of 8.8%. This faster trajectory is linked to higher-value biologics and the continued role of intravenous treatment in patients with serious ischemic manifestations. Tocilizumab products can be administered subcutaneously, while several formulations also support intravenous use; for example, FDA labeling for Avtozma includes both intravenous and subcutaneous dosing in adult GCA. These options allow treatment to move between institution-based administration and trained home injection depending on patient and payer requirements.

 

Distribution Channels Driving Temporal Arteritis Market Value

Hospital pharmacies play a critical role in the emergency management, ongoing clinical optimization, and safe transitions of care for patients with Temporal Arteritis, also known as Giant Cell Arteritis (GCA). In 2025, hospital pharmacies accounted for 48.0% of the Temporal Arteritis Market, valued at USD 0.758 billion, and are projected to expand at a CAGR of 7.4%. Their importance is driven by timely access to corticosteroids and other therapies, medication management, dose optimization, monitoring, and coordinated care across multidisciplinary clinical teams.

Retail pharmacies represented 37.0% share, valued at USD 0.585 billion in 2025, and are expected to grow at a CAGR of 6.0%. The channel primarily serves outpatient corticosteroid tapering, conventional immunosuppressants and oral targeted treatment. Because many GCA patients remain on medication for extended periods after acute disease control, repeat prescriptions create a substantial recurring outpatient dispensing component even when specialist monitoring remains hospital- or clinic-led.

Online pharmacies accounted for 15.0% of the market, representing USD 0.237 billion in 2025, and are projected to expand at a CAGR of 10.6%, the fastest rate among distribution channels. Their role is strongest for stable patients receiving oral maintenance therapy rather than acute GCA management. Prednisone, methotrexate and oral targeted agents can support refill and delivery-based pharmacy models once treatment has been established and appropriate clinical monitoring is in place.

 

Regional Growth Pathways Shaping the Temporal Arteritis Market

North America held a significant 42.0% share of the Temporal Arteritis Market in 2025, valued at approximately USD 0.664 billion, and is expected to grow at a CAGR of 7.5% from 2026 to 2032. The region’s approach to Temporal Arteritis, clinically known as Giant Cell Arteritis (GCA), is characterized by standardized healthcare networks, reliance on established diagnostic procedures, and rapid adoption of advanced targeted therapies. These factors are expected to strengthen treatment accessibility, outcomes, and overall market growth across the region.

Europe represented 29.0% of the global market in 2025, with a market value of USD 0.458 billion, and is projected to expand at a CAGR of 6.9% during the forecast period. The region is characterized by a strong shift toward non-invasive imaging technologies, driven by growing clinical preference for safer and more efficient diagnostic approaches. In parallel, the rapid implementation of specialized multidisciplinary networks is enhancing collaboration among healthcare professionals, supporting improved diagnosis, treatment planning, and patient management across Europe.

Asia-Pacific (APAC) region reflects a unique intersection of genetic diversity and rapidly advancing healthcare infrastructure, creating significant opportunities for market growth. In 2025, APAC accounted for 18.0% of the global market, representing approximately USD 0.284 billion. The region is projected to register the fastest regional CAGR of 8.7% during the forecast period.

Latin America accounted for 6.0% of the Temporal Arteritis Market, valued at USD 0.095 billion in 2025, and is projected to expand at a CAGR of 6.4%. Commercial activity remains concentrated in major urban referral hospitals where rheumatology, ophthalmology, pathology and advanced imaging can be coordinated. Wider ultrasound use offers a comparatively practical route to faster specialist diagnosis, while higher-cost targeted treatment remains more closely tied to reimbursement and tertiary-care access.

Middle East & Africa represented 5.0% share, valued at USD 0.079 billion in 2025, and is projected to grow at a CAGR of 6.4%. Published epidemiological evidence indicates substantially lower reported GCA incidence in African and Middle Eastern populations than in Scandinavian populations. Consequently, market development is more closely linked to case recognition, specialist referral and access to appropriate vascular imaging and immunosuppressive therapy than to assumptions of a large underlying treatment-eligible population.

 

Key Companies Driving Innovation in the Temporal Arteritis Market

Competition in the Temporal Arteritis Market centers on steroid-sparing efficacy, route of administration, safety in an older patient population, biologic versus oral treatment, price competition from biosimilars, and payer positioning. Roche/Genentech retains an established clinical position through IL-6 inhibition, AbbVie has introduced a differentiated oral JAK approach, and biosimilar suppliers are competing increasingly through contracting and procurement.

Roche/Genentech in the Temporal Arteritis Market

Portfolio: Actemra/RoActemra (tocilizumab)

Roche and Genentech established the modern targeted GCA treatment category through Actemra, an IL-6 receptor inhibitor. Its principal competitive advantage is no longer novelty but its entrenched clinical position: tocilizumab is incorporated into specialist treatment guidelines, reimbursement pathways and years of rheumatology practice.

Its commercial challenge is biosimilar erosion. As Tyenne, Avtozma and Tofidence broaden competition, Roche must defend the reference product against lower-cost procurement while targeted competition from Rinvoq challenges IL-6 inhibition at the mechanism and administration-route level.

 

AbbVie in the Temporal Arteritis Market

Portfolio: Rinvoq (upadacitinib)

AbbVie is the most important recent branded entrant after securing FDA approval for adult GCA on April 28, 2025, with U.S. orphan exclusivity for the GCA indication extending to April 28, 2032. SELECT-GCA gives the company a differentiated oral treatment proposition supported by superior Week 52 sustained remission versus the study control regimen.

The principal commercial issue for AbbVie is market access rather than clinical differentiation alone. Germany completed its formal benefit assessment in November 2025, while NICE's appraisal remains in development in the UK. The resulting country-by-country reimbursement environment will determine how readily Rinvoq can compete with established and increasingly lower-cost tocilizumab therapies.

 

Fresenius Kabi in the Temporal Arteritis Market

Portfolio: Tyenne (tocilizumab-aazg)

Fresenius Kabi competes directly in the IL-6 category through Tyenne, a biosimilar to Actemra with an FDA-labeled adult GCA indication. FDA records cover intravenous and subcutaneous presentations, giving the company access to institutional as well as outpatient administration pathways.

Tyenne's strategic role is primarily economic: it gives payers and hospital procurement organizations another tocilizumab option. Its inclusion in the NHS biosimilar framework illustrates how biosimilar competition can alter purchasing behavior even without introducing a new treatment mechanism.

 

Celltrion in the Temporal Arteritis Market

Portfolio: Avtozma (tocilizumab-anoh)

Celltrion received FDA approval for Avtozma on January 24, 2025, including treatment of adult GCA. Its label supports both intravenous and subcutaneous administration, giving it direct overlap with the established Actemra treatment pathway.

Avtozma also entered NHS biosimilar procurement in 2026. Celltrion therefore competes primarily through price, contracting and supply reliability rather than a new mechanism, and its expansion increases pressure on reference tocilizumab pricing and branded therapies seeking a premium over the IL-6 class.

 

Biogen in the Temporal Arteritis Market

Portfolio: Tofidence (tocilizumab-bavi)

Biogen's Tofidence further expands U.S. biosimilar competition. FDA's Purple Book identifies Tofidence as a biosimilar to Actemra and lists Biogen MA Inc. as the applicant, with original U.S. approval dating to September 2023.

Its commercial relevance to the broader GCA treatment environment is tied less to therapeutic differentiation and more to class-level price competition, formulary contracting and the ability of biosimilars to preserve IL-6 treatment share as Rinvoq enters the same steroid-sparing patient pool.

 

Novartis in the Temporal Arteritis Market

Portfolio Relevant to GCA Development: Cosentyx (secukinumab)

Novartis was positioned to introduce an IL-17 pathway competitor through the Phase III GCAptAIN trial. The study, NCT04930094, enrolled 354 patients and was completed in February 2026. Novartis announced in July 2025 that the study did not meet its primary endpoint of sustained remission at Week 52, while key secondary outcomes also failed to establish statistical superiority.

This failure has competitive significance even though it did not produce a commercial GCA product. It removes a potential near-term mechanism challenger and leaves the targeted Temporal Arteritis Market more concentrated around tocilizumab-class IL-6 inhibition and AbbVie's JAK strategy.

 

Analyst Commentary: From Steroid Dependence to Precision-Controlled Temporal Arteritis Care

The Temporal Arteritis Market is approaching a structural shift as treatment moves beyond prolonged corticosteroid dependence toward targeted, steroid-sparing disease control. The most significant near-term pharmaceutical breakthrough is likely to come from JAK inhibition, led by Rinvoq (upadacitinib). Its oral administration differentiates it from injectable biologics and could support broader outpatient adoption, particularly if longer-term evidence continues to demonstrate durable remission with reduced corticosteroid exposure.

At the same time, tocilizumab biosimilars are expected to reshape market economics rather than treatment science. Products such as Tyenne, Avtozma and Tofidence could expand access to IL-6 inhibition while intensifying price competition, potentially forcing newer therapies to demonstrate stronger clinical and health-economic differentiation.

The next major innovation may emerge from diagnostic technology rather than another drug class. Temporal and axillary artery ultrasound is increasingly positioned as a frontline alternative to biopsy, enabling faster diagnosis through specialized fast-track pathways. Over time, quantitative ultrasound and AI-assisted image interpretation could improve identification of persistent vascular inflammation and relapse risk.

A further breakthrough opportunity lies in precision disease monitoring. Conventional ESR and CRP become less informative during IL-6 blockade, creating demand for new biomarkers and advanced imaging tools. Molecular PET approaches targeting activated macrophages, alongside multimodal models combining imaging, biomarkers and clinical data, could eventually allow physicians to determine which patients require prolonged targeted therapy.

Overall, the market's next growth phase will be driven by therapies and technologies that achieve three objectives simultaneously: sustained remission, lower corticosteroid exposure and earlier identification of relapse.

 

Temporal Arteritis Market Methodology Intelligence and Forecasting Framework

The Temporal Arteritis Market assessment used a secondary-research-led, top-down and bottom-up triangulation framework. Strategic Market Research was used as the baseline source for the 2025 global market value of USD 1.58 billion, 2032 forecast of USD 2.61 billion, 7.43% CAGR, and reported drug-class, route-of-administration, distribution-channel, and regional splits.

Market sizing was cross-checked by reconciling each segment’s 2025 revenue with the total market and testing forecast values using the standard CAGR formula. Regional estimates were evaluated against the population aged 50 years and older, reported GCA incidence and prevalence, diagnosed patient pools, rheumatology and ophthalmology access, temporal-artery imaging and biopsy availability, treatment utilization, reimbursement conditions, biologic penetration, and access to newer steroid-sparing therapies.

Epidemiology and disease-burden assumptions were benchmarked against peer-reviewed systematic reviews and meta-analyses indexed in PubMed. Published meta-analysis evidence reports pooled GCA incidence of approximately 10 cases per 100,000 people aged over 50 and pooled prevalence of approximately 51.7 per 100,000, with substantially higher incidence reported in Scandinavian and other Northern European populations. Regional studies, including U.S. data, were used to account for geographic variation rather than applying a single global incidence assumption.

Treatment, mechanism-of-action, and clinical-evidence analysis relied primarily on FDA databases, ClinicalTrials.gov, ACR/Vasculitis Foundation guidance, EULAR recommendations, and official manufacturer disclosures. ClinicalTrials.gov was used to validate SELECT-GCA, the Phase III upadacitinib study enrolling 429 participants, while FDA Orphan Drug records confirmed Rinvoq's approval for adult GCA on April 28, 2025. ACR guidance was used to assess the positioning of glucocorticoids, tocilizumab, and methotrexate, while EULAR imaging recommendations supported analysis of ultrasound and other vascular-imaging pathways in GCA diagnosis and monitoring.

Biologic and biosimilar competition was validated through FDA approval records and the Purple Book. These sources were used to distinguish reference tocilizumab from competing products including Tyenne, Avtozma, and Tofidence, and to evaluate intravenous versus subcutaneous availability, biosimilar status, market-access implications, and potential price pressure within the IL-6 inhibitor class. FDA records confirm Avtozma's January 2025 approval and Tyenne's expanding IV and subcutaneous presentations.

Pipeline and competitive-risk analysis incorporated both successful and unsuccessful late-stage programs. Novartis' Phase III GCAptAIN study of secukinumab was reviewed through ClinicalTrials.gov and company disclosures; the trial was completed, while Novartis reported in July 2025 that it failed to meet its primary sustained-remission endpoint. This was incorporated when assessing the probability of near-term mechanism diversification beyond IL-6 and JAK inhibition.

Regional commercialization assumptions were additionally evaluated against health-technology assessment and reimbursement activity, including Germany's G-BA assessment of upadacitinib for GCA and the ongoing NICE technology appraisal in the United Kingdom. These sources helped differentiate regulatory approval from actual market access and reimbursement maturity.

Competitive analysis compared companies by drug class, mechanism differentiation, steroid-sparing potential, sustained-remission evidence, route of administration, dosing convenience, safety in an older patient population, biosimilar exposure, regulatory status, reimbursement positioning, and commercialization readiness. Particular emphasis was placed on Roche/Genentech, AbbVie, Fresenius Kabi, Celltrion, Biogen, and relevant late-stage developers.

Final estimates were triangulated across market research benchmarks, epidemiology, clinical guidelines, trial evidence, regulatory databases, reimbursement assessments, and company disclosures, with greater weight assigned to government and regulatory databases, ClinicalTrials.gov, peer-reviewed literature, professional-society guidance, health-technology assessment agencies, and recent primary company materials.

 

Temporal Arteritis Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 1.58 Billion
Revenue Forecast in 2032	USD 2.61 Billion
Overall Growth Rate	CAGR of 7.43% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Billion
Segmentation	By Drug Class, By Route of Administration, By Distribution Channel, and By Geography
By Drug Class	Corticosteroids; Interleukin-6 Inhibitors; Immunosuppressants; JAK Inhibitors
By Route of Administration	Oral; Parenteral
By Distribution Channel	Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
By Geography	North America; Europe; Asia Pacific; Latin America; Middle East & Africa
By Region	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Country Scope	U.S., Canada, U.K., Germany, France, Italy, Spain, China, Japan, India, South Korea, Brazil, Mexico, Saudi Arabia, U.A.E., South Africa
Market Drivers	An aging at-risk population, the consequences of delayed diagnosis, recurrent disease requiring long-term management, and wider adoption of targeted steroid-sparing therapies
Customization Option	Available upon request